Takeda Pharmaceutical (TAK) Receivables - Net (2017 - 2026)

Takeda Pharmaceutical has reported Receivables - Net for 10 years, with the latest figure at $5.8 billion in Q2 2026.

• On a quarterly basis, Receivables - Net rose 26.89% year-over-year to $5.8 billion in Q2 2026; TTM through Jun 2026 was $5.8 billion, a 26.89% increase from a year earlier, with the FY2026 full-year figure at $6.2 billion, up 23.15% from the prior year.
• Receivables - Net was $5.8 billion for Q2 2026 at Takeda Pharmaceutical, up from $5.4 billion in the prior quarter.
• The five-year high for Receivables - Net was $6.1 billion in Q1 2022, with the low at $4.6 billion in Q2 2025.
• Average Receivables - Net over 5 years is $5.2 billion, with a median of $5.0 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Receivables - Net decreased 28.2% in 2022, then gained 26.89% in 2026.
• Over 5 years, Receivables - Net stood at $5.0 billion in 2022, then fell by 3.22% to $4.8 billion in 2023, then declined by 3.42% to $4.7 billion in 2024, then increased by 2.26% to $4.8 billion in 2025, then increased by 21.98% to $5.8 billion in 2026.
• The last three Receivables - Net figures came in at $5.8 billion (Q2 2026), $5.4 billion (Q1 2026), and $4.8 billion (Q4 2025), per Business Quant data.